Related Experiment Videos
The effect of vertical pulsating stimulation on apnea of prematurity
1Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Insights
Vagal nerve stimulation (VPS) reduced central and mixed apnea in preterm infants but did not affect obstructive apnea. VPS is a safe, noninvasive option for treating apnea of prematurity, warranting further study for long-term efficacy.
Area of Science:
- Neonatal Medicine
- Respiratory Physiology
- Pediatric Neurology
Background:
- Apnea of prematurity (AOP) is a common respiratory challenge in preterm infants.
- Idiopathic apnea of prematurity necessitates effective, safe interventions.
- Current treatments for AOP have limitations.
Purpose of the Study:
- To evaluate the efficacy of vagal nerve stimulation (VPS) in managing idiopathic apnea of prematurity.
- To assess VPS's impact on respiratory effort and apneic episodes in preterm infants.
Main Methods:
- Preterm infants with idiopathic apnea of prematurity were placed on VPS.
- Respiratory effort and the frequency of apneic episodes were monitored.
- Apnea types (central, mixed, obstructive) were differentiated.
Main Results:
- VPS positively influenced respiratory effort in preterm infants.
- A significant reduction in central and mixed apneic episodes was observed with VPS.
- VPS did not demonstrate benefits in reducing obstructive apnea.
Conclusions:
- VPS is a promising, noninvasive intervention for central and mixed apnea of prematurity.
- Given its safety and ease of use, VPS should be considered before other treatments.
- Further research is needed to establish VPS's long-term effectiveness for AOP.
Abstract:
Placing preterm infants suffering idiopathic apnea of prematurity on the VPS had an effect on the infants' respiratory effort and achieved a reduction in the number of apneic episodes secondary to central and mixed apnea. However, VPS offered no benefits in the reduction of obstructive apnea in this study population. Because central apnea has been reported as the predominant type of apnea and VPS is a nontoxic, noninvasive, and easy-to-implement method of alleviating central and mixed apnea types, it seems prudent to give VPS which has the stimulus characteristics to preterm infants experiencing apnea of prematurity before other treatment modalities currently in use are tried. Further studies are warranted to determine if VPS is effective in a continuous long-term treatment for apnea of prematurity, for example, until the end of apnea.